Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy

Jiang, Hong; Pei, Lei; Liu, Nannan; Li, Junsheng; Li, Zhengrong; Zhang, Shumei

doi:10.3109/10717544.2015.1048491

Cited by 37 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EE % significantly affects the release of the drug from NLCs as higher encapsulation alter the concentration gradient and rate of drug release. EE % values more than 60% usually indicate the success of the preparation method in loading a proper amount of the drug in the lipid particles [32,65,71].…”

Section: Encapsulation Efficiency Percentage (Ee %)mentioning

confidence: 99%

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

et al. 2020

View full text Add to dashboard Cite

The efficacy of current standard chemotherapy is suboptimal due to the poor solubility and short half-lives of chemotherapeutic agents, as well as their high toxicity and lack of specificity which may result in severe side effects, noncompliance and patient inconvenience. The application of nanotechnology has revolutionized the pharmaceutical industry and attracted increasing attention as a significant means for optimizing the delivery of chemotherapeutic agents and enhancing their efficiency and safety profiles. Nanostructured lipid carriers (NLCs) are lipid-based formulations that have been broadly studied as drug delivery systems. They have a solid matrix at room temperature and are considered superior to many other traditional lipid-based nanocarriers such as nanoemulsions, liposomes and solid lipid nanoparticles (SLNs) due to their enhanced physical stability, improved drug loading capacity, and biocompatibility. This review focuses on the latest advances in the use of NLCs as drug delivery systems and their preparation and characterization techniques with special emphasis on their applications as delivery systems for chemotherapeutic agents and different strategies for their use in tumor targeting.

show abstract

Section: Encapsulation Efficiency Percentage (Ee %)mentioning

confidence: 99%

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The nanosize of NLCs promotes drug absorption through the stratum corneum, it is the outermost barrier of epidermis that able to retard the drug penetration into the skin [9]. Aim of this study was to investigate and assess the potential of Docetaxel-loaded NLCs for the treatment of skin cancer using skin cancer cell line [2,10,11].…”

Section: Introductionmentioning

confidence: 99%

Dermal Delivery of Docetaxel Loaded Nano Liquid Crystals for the Treatment of Skin Cancer

Majumdar

Dubey

2019

Int J App Pharm

View full text Add to dashboard Cite

Objective: The aim of the present study is to develop docetaxel-loaded nano liquid crystals (NLCs) to enhanced and effective delivery of the drug to the skin cancer. Methods: NLCs bearing docetaxel were prepared by an emulsification solvent diffusion method. The formulated NLCs were characterized for average particle size, polydispersity index (PDI) Zeta potential, entrapment efficiency and in vitro drug release study. The prepared formulations were studied for it's in vitro cell line and cell uptake study. Results: It was revealed that the average size of NLCs was found 178.3±5.07, PDI was 0.189, percent entrapment efficiency was found 71.3±2.49 and Zeta potential was found-17.3±2.4. In vitro release determined by Franz diffusion cell was found 61.6±3.2% after 72 hr. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Docetaxel loaded NLCs were giving more cytotoxicity as compared to the plain drug. The cell uptake study was found enhanced uptake of fluorescein isothiocyanate (FITC) loaded NLCs in comparison to plain FITC. Docetaxel and docetaxel-loaded NLCs showed 28.3±0.3 and 39.3±1.3 growth inhibition respectively after 48h upon incubation at 0.5 µg/ml concentration (p<0.05). Conclusion: The result of the studies was concluded that NLCs can be used as impending drug delivery system which may enhance the drug uptake and maintain the drug level for longer period of time and it is potential carrier system which can be used for the treatment of skin diseases like cancer.

show abstract

“…Tumor volume of ETP-CUR-NLCs group was obviously the smallest among all groups. The TIR of different groups are illustrated in (Jiang et al, 2015). The aim of this study was to further investigate the synergistic effect of ETP and CUR against SGC 7901 cells.…”

Section: In Vitro Cytotoxicity Studymentioning

confidence: 99%

“…ETP-CUR-NLCs were constructed by the solvent injection technique (Jiang et al, 2015). ETP (5 mg), CUR (1 mg), GM (25 mg), SPC (25 mg) and oleic acid (5 mL) were mixed and heated at 70 C to form the oil phase.…”

Section: Preparation Of Etp-cur-nlcsmentioning

confidence: 99%

See 1 more Smart Citation

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Jiang

Geng²,

Liu³

et al. 2016

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Context: Gastric carcinoma (GC) is one of the most common cancers and the second most frequent cause of cancer-related deaths. Chemotherapy is an important therapeutic modality for GC. However, chemoresistance limited its success rate. Combination chemotherapy is often applied to prevent drug-induced resistance in cancers.Objective: The aim of this study is to evaluate whether the co-delivery of etoposide (ETP) and curcumin (CUR) with one nanoparticle can result in synergistic effects of both drugs. Methods: ETP-and CUR-loaded nanostructured lipid carriers (ETP-CUR-NLC) were prepared by the solvent injection technique. Their average size, zeta potential and drug loading were evaluated. Human gastric cancer cell lines (SGC7901 cells) were used for the testing of in vitro cytotoxicity studies, and in vivo anti-tumor efficacies of the carriers were evaluated on mice bearing SGC7901 cells xenografts.Results: ETP-CUR-NLC has a particle size of 114 nm, EPT-loading quantity of 83% and CURloading quantity of 82%. ETP-CUR-NLC displayed high cytotoxicity and enhanced antitumor activity in vitro and in vivo. Meanwhile, ETP-CUR-NLC displayed low cytotoxicity in normal tissues in vivo. Discussion and conclusion: The results demonstrate that ETP-CUR-NLC can achieve impressive anti-tumor activity. By combining CUR, an effective NF-kB inhibitor, with ETP, a powerful anticancer drug, in NLC, we could improve the therapeutic efficacy in cancer treatments. Our results showed that such co-loaded delivery systems could serve as a promising therapeutic approach to improve clinical outcomes against various malignancies.

show abstract

Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy

Cited by 37 publications

References 21 publications

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

Dermal Delivery of Docetaxel Loaded Nano Liquid Crystals for the Treatment of Skin Cancer

Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors

Contact Info

Product

Resources

About